Trabectedin for desmoplastic small round cell tumours: a possible treatment option?

Conclusions This report supports Trabectedin to be active and safe in pre-treated DSRCT patients. Further prospective and collaborative efforts are desirable to better define its role in the management of this disease.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research